Trials / Completed
CompletedNCT02320669
Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 220 (actual)
- Sponsor
- Seattle Children's Hospital · Academic / Other
- Sex
- All
- Age
- 5 Months
- Healthy volunteers
- Not accepted
Summary
This is a study to determine the safety and efficacy of liothyronine sodium/triiodothyronine (Triostat), a synthetic thyroid hormone, when given to infants with congenital heart disease during cardiopulmonary bypass surgery. Funding Source - FDA OOPD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Triostat | Bolus of Triiodothyronine followed by infusion for 48 hours |
| DRUG | Placebo | Bolus of Placebo followed by infusion for 48 hours |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2019-10-01
- Completion
- 2019-10-01
- First posted
- 2014-12-19
- Last updated
- 2024-04-09
- Results posted
- 2024-04-09
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02320669. Inclusion in this directory is not an endorsement.